식도암에서 방사선 단독치료와 방사선 및 항암화학요법제 치료의 효과
천선희, Hyun Cheol Chung, 김주항 et al. · The Korean Journal of Internal Medicine · 1988
The role of adjuvant chemotherapy in the treatment of esophageal carcinoma was examined in a review of 84 patients. Between January 1984 to April 1988, 35 patients were treated with radiotherapy alone, 32 patients were treated with combined radiotherapy and chemotherapy (5-fluorouracil(5-Fu) and cisplatin), and 17 patients were untreated due to their economic problems. The 1 and 2-year survival rates among patients treated by radiation were 40% and 0%, respectively, whereas they were 28%, and 14% in patients treated with combined modality, and 40%, and 0% in patients without any treatment. In stage IV disease, the survivals at 1 and 2-years of patients with combined treatment were superior to the survivals of the radiotherapy alone treated group (p<0. 001), In both treatment groups, the actual survival rate was higher in patients with good Eastern Cooperative Oncology Group (ECOG) performance status (p<0.001). Treatment was well tolerated, and acute toxicity included esophagitis, stomatitis, and leukopenia. Late toxicities were predominantly manifestated as stricture, pneumonia, and mediastinitis. This combination of radiation therapy with infusional 5-FU and cisplatin is an effective and relatively well-tolerated regimen in the Treatment of esophageal cancer.
Cited by 0 works.